 |
| This is a beta version of NNDB |
|
|
|
|
|
|
Sector: Pharmaceutical
LISTS
| Company | Sales | Employees |
|---|
| Abbott Laboratories | $22.3B (2005) | 60,000 | | Alkermes | $167M (2006) | 750 | | Allergan | $4.5B (2009) | 5000 | | Alnylam Pharmaceuticals | $5.7M (2005) | 100 | | ALZA Corporation | | | | American Home Products | | | | Amerisource Bergen | $66.1B (2007) | 10,000 (2008) | | Amersham | | 10,000 | | ARIAD Pharmaceuticals | | | | Array BioPharma | $45M (2006) | 275 | | AstraZeneca | $24B (2005) | 65,000 | | Aventis | | | | Barr Pharmaceuticals | $2.50B (2007) | 9000 | | Bindley Western Industries | | | | Biogen | | | | Biogen Idec | $2.26B | 4100 | | Bristol-Myers | | | | Bristol-Myers Squibb | $19.2B (2005) | 43,000 | | Cephalon | $1.21B (2005) | 2900 | | Chiron Corporation | $1.9B (2005) | 5400 | | Ciba-Geigy | | | | Covance | $1.63B (2007) | 8500 | | Cubist Pharmaceuticals | $121M (2005) | 370 | | Curis | $6M (2005) | 70 | | Dyax Corporation | $26.1M (2007) | 175 | | Eli Lilly | $18.6B (2007) | 40,000 | | Enzon Pharmaceuticals | $74M (2005) | 300 | | Forest Laboratories | $3B (2005) | 5000 | | GenVec | $27M (2005) | 110 | | Gilead Sciences | $2.0B (2005) | 1900 | | Hoechst AG | | | | Hospira | $2.6B (2005) | 13,000 | | Human Genome Sciences | $41.8M (2007) | 850 | | ICOS | $71M (2005) | 675 | | Idec | | | | Idenix Pharmaceuticals | $68M (2007) | 219 | | Incyte | $7.9M (2005) | 175 | | Infinity Pharmaceuticals | $35M (2005) | 130 | | Introgen Therapeutics | $1.9M (2005) | 80 | | Ipsen SA | | 3800 | | King Pharmaceuticals | $1.8B (2005) | 2800 | | Light Sciences | | | | Mallinckrodt | | | | MannKind | $10K (2007) | 600 (2008) | | Marion Laboratories | $930M (1989) | | | MedImmune | $1.2B (2005) | 2000 | | Merck | $22.0B (2005) | 60,000 | | Millennium Pharmaceuticals | $487M (2006) | 1150 | | Momenta Pharmaceuticals | $14.5M (2005) | 100 | | Mylan Laboratories | $1.3B (2006) | 2900 | | Nadro | | | | Nektar Therapeutics | $126M (2005) | 775 | | Neurogen | $6.8M (2003) | 155 (2003) | | Novartis | $25B | 90,000 | | Novo Nordisk | $920M (2004) | 23,000 | | OSI Pharmaceuticals | $174M (2005) | 650 | | Ovation Pharmaceuticals | | 150 | | Parke-Davis | | | | Pfizer | $45.1B (2003) | 122,000 (2003) | | Pharmacia | | | | Pharmacia & Upjohn | | | | Purdue Pharma | | | | Regeneron | $66M (2006) | 600 | | Roche | | 70,000 | | Sandoz | | | | Sanofi-Aventis | $34B (2005) | 97,000 | | Sanofi-Synthlabo | | | | Schering-Plough | $8.3B (2003) | 30500 (2003) | | Scios | | | | Searle Pharmaceuticals | | | | Squibb | | | | Takeda Pharmaceutical | | 16,000 | | Teva Pharmaceutical Industries | | 15,000 | | Theravance | $12M (2005) | 270 | | Upjohn | | | | Valeant Pharmaceuticals | $824M (2005) | 3750 | | Vertex Pharmaceuticals | $161M (2005) | 800 | | Vical | $12M (2005) | 150 | | ViroPharma | $132M (2005) | 50 | | Warner-Lambert | | | | Watson Pharmaceuticals | $1.6B (2005) | 3800 | | Wyeth | $22.4B (2007) | 50000 |
Copyright ©2025
|
|
|
🎄
Merry Christmas
or happy holidays, whatever
from the NNDB staff
❄️ ⭐ ❄️
📚
Bibliographies
NNDB has added thousands of bibliographies for people, organizations, schools, and general topics — listing more than 50,000 books and 120,000 other references.
Access via the "Bibliography" tab or the "Related Topics" sidebar.
|